Trial Identifier: | D5160C00017 |
Sponsor: | AstraZeneca |
NCTID:: | NCT02442349 |
Start Date: | June 2015 |
Primary Completion Date: | March 2016 |
Study Completion Date: | December 2022 |
Condition: | Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
Country | Location |
---|---|
Australia | Heidelberg, Australia, 3084 |
Australia | Kogarah, Australia, 2217 |
Australia | Kurralta Park, Australia, 5037 |
Australia | Nedlands, Australia, 6009 |
Australia | Woolloongabba, Australia, 4102 |
China | Beijing, China, 100730 |
China | Beijing, China, 100142 |
China | Beijing, China, 100021 |
China | Beijing, China, 100071 |
China | Changchun, China, 130000 |
China | Chengdu, China, 610041 |
China | Chongqing, China, 400038 |
China | Chongqing, China, 400042 |
China | Fuzhou, China, 350014 |
China | Guangzhou, China, 510100 |
China | Haikou, China, 570311 |
China | hangzhou, China, 310006 |
China | Hangzhou, China, 310003 |
China | Hangzhou, China, 310022 |
China | Harbin, China, 150049 |
China | jinan, China, 2501117 |
China | Nanjing, China, 210009 |
China | Shanghai, China, 200030 |
China | Shanghai, China, 200032 |
China | Shanghai, China, CN-200433 |
China | Tianjin, China, 300060 |
China | Wuhan, China, 430030 |
China | Wuhan, China, 430022 |
China | xi'an, China, 710038 |
China | Xi'an, China, 710032 |
China | Zhengzhou, China, 450008 |
South Korea | Goyang-si, South Korea, 10408 |
South Korea | Seongnam-si, South Korea, 13620 |
South Korea | Seoul, South Korea, 05505 |
South Korea | Seoul, South Korea, 135-710 |
Vietnam | Ha Noi, Vietnam, 100000 |
Vietnam | Hanoi, Vietnam, 100000 |
Vietnam | Ho Chi Minh city, Vietnam |
Vietnam | Ho Chi Minh City, Vietnam, 700000 |